Daniel A Hogan, MD in North English, IA - Family Medicine

Daniel A Hogan, MD is a Family Medicine physician based in North English, Iowa. Daniel A Hogan is licensed to practice in Iowa (license number 21104) and his current practice location is 402 S Walnut St, North English, Iowa. He can be reached at his office (for appointments etc.) via phone at (319) 664-3211.

NPI number for Daniel A Hogan is 1295777407 and his current mailing address is Po Box 2027, Iowa City, Iowa. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1295777407.

Contact Information

	Daniel A Hogan, MD
	402 S Walnut St, North English, IA 52316-9559
	(319) 664-3211
	(319) 664-3212

Physician's Profile

Full Name	Daniel A Hogan
Gender	Male
Speciality	Family Medicine
Location	402 S Walnut St, North English, Iowa
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1295777407
Provider Enumeration Date: 06/12/2006
Last Update Date: 03/06/2015

Medical Identifiers

Medical identifiers for Daniel A Hogan such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1295777407	NPI	-	NPPES
080080484	Other	IA	RAILROAD MEDICARE
3173765	Medicaid	IA

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207Q00000X	Family Medicine	21104 (Iowa)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Daniel A Hogan is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Daniel A Hogan, MD Po Box 2027, Iowa City, IA 52244-2027 Ph: (319) 339-3541	Daniel A Hogan, MD 402 S Walnut St, North English, IA 52316-9559 Ph: (319) 664-3211

News Archive

Spectrum Pharmaceuticals, Handok Pharmaceuticals sign collaboration agreement

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, and Handok Pharmaceuticals Co., Ltd., a fully integrated Korean pharmaceutical company, today announced a collaboration for the development and commercialization of apaziquone in South Korea. Apaziquone is an antineoplastic agent currently being investigated for the treatment of non-muscle invasive bladder cancer by intravesical instillation.

Study compares different strategies to prevent malaria among pregnant women in sub Saharan Africa

A novel strategy to screen pregnant women for malaria with rapid diagnostic tests and treat the test-positive women with effective antimalarials does not lower the risk of adverse pregnancy outcomes compared with treating all pregnant women with the malaria preventive sulfadoxine-pyrimethamine (SP) in sub-Saharan Africa, according to an open label randomized trial published this week in PLOS Medicine by Feiko ter Kuile, of the Liverpool School of Tropical Medicine, and colleagues.

How the brain processes pain location

Is that pain in your chest a heart attack or indigestion? New research from Wake Forest University School of Medicine reveals that more areas of the brain than previously thought are involved in determining the location of pain.

Union Springs, BIOSAFE enter agreement to commercialize HM4100 products

Kentucky-based Union Springs Pharmaceuticals announced today an agreement with BIOSAFE® of Pittsburgh to market products containing the patented and novel antimicrobial polymer, HM4100. Similar to its flagship product, MyClyns (antimicrobial germ spray), Union Springs Pharmaceuticals will identify the products as MyClyns Antimicrobial Surface Treatments and will be the first company to bring these unique products to the market.

A novel gene therapy strategy may help reduce seizures in adults suffering from epilepsy

Deborah Lin, from the Faculty of Medical and Health Sciences, is investigating the effects of a therapeutic gene transfer in a particular form of epilepsy which affects the brain's temporal lobe region.

Daniel A Hogan, MD - Family Medicine in North English, IA